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Abstract 
Transforming growth factor-beta (TGF-β)/bone morphogenic protein (BMP) signaling is in-
volved in a vast majority of cellular processes and is fundamentally important throughout life. 
TGF-β/BMPs have widely recognized roles in bone formation during mammalian development 
and exhibit versatile regulatory functions in the body. Signaling transduction by TGF-β/BMPs is 
specifically through both canonical Smad-dependent pathways (TGF-β/BMP ligands, receptors 
and  Smads)  and  non-canonical  Smad-independent  signaling  pathway  (e.g.  p38  mito-
gen-activated protein kinase pathway, MAPK). Following TGF-β/BMP induction, both the 
Smad and p38 MAPK pathways converge at the Runx2 gene to control mesenchymal pre-
cursor  cell  differentiation.  The  coordinated  activity  of  Runx2  and  TGF-β/BMP-activated 
Smads is critical for formation of the skeleton. Recent advances in molecular and genetic 
studies using gene targeting in mice enable a better understanding of TGF-β/BMP signaling in 
bone and in the signaling networks underlying osteoblast differentiation and bone formation. 
This review summarizes the recent advances in our understanding of TGF-β/BMP signaling in 
bone from studies of genetic mouse models and human diseases caused by the disruption of 
TGF-β/BMP signaling. This review also highlights the different modes of cross-talk between 
TGF-β/BMP signaling and the signaling pathways of MAPK, Wnt, Hedgehog, Notch, and FGF in 
osteoblast differentiation and bone formation. 
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INTRODUCTION 
Bone  is  formed  through  two  distinct  phases: 
endochondral ossification, in which a cartilage model 
is replaced by bone, and intramembranous ossifica-
tion,  in  which  bones  are  shaped  directly  from  con-
densations of mesenchymal cells without a cartilage 
intermediate  (1).  Bone  is  continuously  remodeled 
throughout life and an imbalance in this process can 
result in bone disease. The integrity and function of 
bone are maintained by an exquisite balance between 
osteoblasts and osteoclasts, the two major bone cells 
involved in the bone remodeling process. Osteoblasts 
are responsible for bone formation, while osteoclasts 
are the bone-resorbing cells (1-2).  
The  transforming  growth  factor-beta  (TGF-β) 
superfamily is comprised of over forty members, such 
as TGF-βs, Nodal, Activin, and bone morphogenetic 
proteins  (BMPs)  (3).  TGF-β  signaling  first  transmits 
signals  across  the  plasma  membrane  through  the 
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formation of heteromeric complexes of specific type I 
and  type  II  serine/threonine  kinase  receptors.  The 
type I receptor is phosphorylated following the acti-
vation of specific type II receptor (4). Activated type I 
receptors  initiate  intracellular  signaling  through 
phosphorylation of specific Smad proteins, R-Smads. 
Activated R-Smads form a complex with co-Smad and 
Smad4 and then translocate into the nucleus to direct 
transcriptional response (5) (Figure 1, 2). 
TGF-β/BMPs  have  widely  recognized  roles  in 
bone formation during mammalian development and 
exhibit versatile functions in the body  (6-7). For in-
stance, a BMP morphogen gradient is established in a 
multicellular embryo, and BMP drives the differenti-
ation  of  ectodermal  cells  and  mediates  dorsal  pat-
terning  to  establish  dorsal-ventral  axis  (8).  Disrup-
tions of TGF-β/BMP signaling have been implicated 
in multiple bone diseases including tumor metastasis, 
brachydactyly  type  A2,  and  osteoarthritis  (9-11).  In 
this  review,  we  will  summarize  novel  discoveries 
from  recent  decades  regarding  the  regulations  of 
TGF-β/BMP signaling in bone as well as the different 
modes  of  cross-talk  between  TGF-β/BMP  signaling 
and the signaling pathways of MAPK, Wnt, Hedge-
hog,  Notch,  and  FGF.  These  new  insights  into 
TGF-β/BMP  signaling  on  bone  will  open  new  pro-
spects for generating novel therapies against clinical 
disorders. 
 
 
 
Figure 1. TGF-β signaling and negative regulation in bone formation. Canonical Smad-dependent TGF-β signaling first binds to receptor 
type II (R-II) and receptor type I (R-I), and then signaling transduces to their Smads. Activated Smads form a complex with Smad4 and then 
translocate into the nucleus where they interact with other transcription factors to trigger target gene expression. Smad7 disrupts the 
activated Smad2/3 to form a complex with Smad4. The non-Smad-dependent TAK1 signaling pathway also regulates bone formation. PTH 
binding activates PTH1R to stimulate several downstream effectors. PTH binding also drives internalization of PTH1R-TGFβRII complex, 
which attenuates both TGF-β and PTH signaling on bone development. Transcriptional factor cAMP response element binding protein 
(CREB) mediates PTH signaling in osteoblasts. P: phosphorylation; Ub: ubiquitination. Int. J. Biol. Sci. 2012, 8 
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Figure 2. BMP signaling and negative regulation in bone formation. Smad-dependent-BMP signaling binds to receptor type II (R-II) and 
receptor type I (R-I) and then the signaling transduces to their Smads. Activated Smads form a complex with Smad4 and then translocate 
into the nucleus where they interact with other transcription factors to trigger target gene expression. Neogenin regulates BMP receptor 
association and Smad1/5/8 signaling. Activated Smads regulate expression of transcriptional factors and transcriptional coactivators 
important  in  osteoblasts  (Dlx5,  Runx2  and  Osx).  Smad6  binds  type  I  BMP  receptor  and  prevents  Smad1/5/8  to  be  activated. 
Non-Smad-dependent TAK1 signaling pathway also regulates bone formation. The interplay between BMPs and Wnt signaling affects bone 
formation (99). BMPRIA signaling upregulates Sost expression primarily through Smad-dependent signaling, while it upregulates DKK1 
through Smad-dependent and non-Smad-dependent signaling. Both Sost and DKK1 inhibit canonical Wnt signaling, leading to a decrease 
in bone mass. P: phosphorylation; Ub: ubiquitination. 
 
 
TGF-β SIGNALING IN OSTEOBLAST 
DIFFERENTIATION AND BONE 
FORMATION 
Autocrine and paracrine stimulation by TGF-β is 
important in the maintenance and expansion of the 
mesenchymal stem/progenitor cells, the progenitors 
of osteoblasts  (12). Bone and cartilage contain large 
amounts of TGF-β and target cells for TGF-β activity. 
At earlier developmental stages, osteoblast-enriched 
populations from fetal bone are more sensitive to the 
mitogenic  effect  of  TGF-β  than  similar  populations 
from  newborns  (13).  Furthermore,  TGF-β  signaling 
also  promotes  osteoprogenitor  proliferation,  early 
differentiation,  and  commitment  to  the  osteoblastic 
lineage through the selective MAPKs and Smad2/3 Int. J. Biol. Sci. 2012, 8 
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pathways,  and  the  cooperation  between  TGF-β  and 
PTH, Wnt, BMP, as well as FGF signaling. 
Canonical TGF-β signaling functions in bone 
(TGF-βs, receptors, Smads) 
TGF-β  isoforms  and  their  receptors,  type  I  re-
ceptor  (TGFβRI  or  ALK5)  and  type  II  receptor 
(TGFβRII  or  Tgfbr2),  play  important  roles  in  endo-
chondral and intramembranous ossification (Table 1). 
TGF-β1 deficient mice display reduced bone growth 
and mineralization (14). TGF-β2 and TGF-β3 double 
knockout mice display a lack of distal parts of the rib 
(15). Mice carrying tissue-specific removal of TGFβRI 
using Dermo1-Cre have short and wide long bones, 
reduced  bone  collars,  and  reduced  trabecular  bone 
(16). Tgfbr2 exhibits functions in the maintenance of 
boundaries  in  the  sclerotome  and  developing  axial 
skeleton  (17).  Conditional  transgenic  mice  with  a 
dominant negative form of Tgfbr2 (dnTgfbr2) devel-
oped hypoplastic cartilage (18). Deletion of Tgfbr2 via 
Col2a1-Cre in mice causes multiple defects in the base 
of  the  skull  and  in  the  vertebrae  (19).  Removal  of 
Tgfbr2 driven by Prx-Cre results in defects in the long 
bones, joints (20), and skull vault (21), indicating that 
Tgfbr2  has  a  critical  role  in  both  intramembranous 
bone  formation  and  endochondral  bone  formation. 
Further  evidence  from  Wnt1-Cre  mediated  tissue 
specific disruption, shows that the loss of Tgfbr2 sig-
naling  leads  to  defects  in  cranial  neural  crest  cells 
(CNCC)-derived  osteoprogenitor  cells  during  in-
tramembranous bone formation (22) (Table 1). 
 
 
Table 1. Conditional knockout models on TGF-β/BMP signaling on bone formation 
Gene  Cre  Defects  Refer 
Tgfbr2 
 
Col2a1-Cre  obvious defects in long bone formation  (18) 
Wnt1-Cre  osteogenic cell proliferation and differentiation  (22) 
Prx1-Cre  short limbs and fusion of the joints in the phalanges  (20) 
Wnt1-Cre  severe defects in mandibular development  (170) 
Col2a-Cre  defects in the base of the skull and in the vertebrae  (19) 
ALK5  Dermo1-Cre  the short bones and ectopic cartilaginous protrusions  (16) 
TAK1  Prx1-Cre  novel embryonic developmental cartilage defects   (171) 
Osx-cre  clavicular hypoplasia and delayed fontanelle fusion  (82) 
Smad7   Prx1-Cre   poor cartilage formation  (172) 
BMP-7  Prx1-Cre  normal postnatal limb growth and maintenance of bone mass  (49) 
Bmp2/Bmp4  Col2a1-Cre  a severe chondrodysplasia phenotype  (53) 
Bmp2  Prx1-Cre  spontaneous fractures  (52) 
Bmp2/Bmp4  Prx1-Cre  a severe impairment of osteogenesis  (50) 
Bmp4  Prx1-Cre  limb skeletogenesis occurs normally in the absence of BMP-4  (51) 
BMPR-II  Prx1-Cre  normal skeleton  (60) 
BMPR-IA  Col1a1-Cre  increased bone volume   (61) 
Col1-CreERTM  increased bone mass   (99) 
Prx1-Cre  shortened limbs and almost complete agenesis of the autopod  (62) 
Smad1  Col1a1-Cre  osteopenic phenotype   (68) 
Col2a1-Cre  calvarial bone development delay  (68) 
Smad1/5  Col2a1-Cre  chondrodysplasia  (69) 
Smad4 
 
TTR-Cre  died at E7.5-E9.5 without head-fold and anterior embryonic structures  (72) 
Mu-Cre  misalignment of the cardiac outflow tract  (74) 
OC-Cre  lower bone mineral density, decreased bone volume, decreased bone formation rate  (26) 
Col2a1-Cre  dwarfism  (41) 
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R-Smads  that  respond  to  TGF-β  receptors  are 
Smad2 and 3. Small C-terminal domain phosphatases 
(SCP)  were  reported  to  be  good  regulators  of 
Smad2/3  activation.  SCP1/2  knockdown  inhibits 
TGF-β  transcriptional  responses  by  dephosphory-
lating Smad2/3 at the linker (inhibitory) but not the 
C-terminal (activating) site (23). Activation of Smad7 
is  another  way  to  control  the  function  of  R-Smads, 
which targets the TGF-β receptor for degradation (24). 
Smad7 mutants that have impaired the ability for the 
recruitment of Smurf2 to  the receptors are compro-
mised  in  their  inhibitory  activity  (25).  Smad7  also 
competes  with  Smad2/3  to  form  complexes  with 
Smad4,  a  common  mediator  for  TGF-β  signaling, 
which  plays  an  essential  role  in  coupling  bone  for-
mation and bone resorption and maintaining normal 
postnatal bone homeostasis (26). 
Recently,  Smad2/3  were  reported  to  directly 
associate  with  the  TRAF6-TAB1-TAK1  molecular 
complex  (27).  Once  TGF-β  signaling  is  blocked,  the 
TRAF6-TAB1-TAK1  molecular  complex  is  not  ob-
served,  indicating  that  TGF-β1  is  indispensable  in 
RANKL-induced  osteoclastogenesis  (28).  TGF-β1 
promotes matrix production and osteoblast differen-
tiation  while  it  reduces  the  ability  of  osteoblasts  to 
secrete  osteoclast  differentiation  factor  RANKL, 
thereby  TGF-β1  indirectly  limits  further  osteoclast 
formation and may affect bone mass. 
Non-canonical TGF-β signaling functions in 
bone 
The  non-Smad-dependent  signaling  pathway 
also  contributes  greatly  to  osteoblast  differentiation 
and bone formation. The study of tamoxifen-inducible 
Cre-ER-mediated  ALK5-deficient  primary  calvarial 
cell culture revealed that TGF-β signaling promotes 
osteoprogenitor  proliferation,  early  differentiation, 
and commitment to the osteoblastic lineage through 
the  selective  MAPKs  and  Smad2/3  pathways  (16). 
TGF-β activation kinase1 (TAK1) and TAK1 binding 
protein 1 (TAB1) play a pivotal role as upstream sig-
nal transducers by activating the MKK3-p38 MAPK 
signaling cascade that leads to the induction of type I 
collagen  expression  by  TGF-β1.  TAK1  has  a  novel 
function in the regulation of the steady-state protein 
levels of MKK3 and p38 MAPK (29) (Figure 1). Recent 
results demonstrate that following TGF-β induction, 
both the Smad and p38 MAPK pathways converge at 
the Runx2 gene to control mesenchymal precursor cell 
differentiation  (30).  In  addition,  ERK  and  p38  also 
differentially mediate TGF-β and BMP-2 function in 
osteoblasts  (31).  TGF-β2-induced  activation  of 
ERK-MAPK is an important signaling component that 
stimulates cell proliferation to enrich osteoprogenitor 
cells, thereby promoting their differentiation into os-
teoblasts to achieve a rapid calvarial bone expansion 
(32). 
Interplay between TGF-β signaling and PTH, 
Wnt, FGF, as well as BMP signaling in bone 
TGF-β and PTH signaling in bone 
Mice with Tgfbr2 deleted in osteoblasts have in-
creased bone mass due to the hyperactivition of PTH 
type I receptor (PTH1R) (33-34). Disruption of PTH 
signaling  by  injection  of  PTH  (7-34)  or  ablation  of 
PTH1R rescues the bone phenotype of these mutant 
mice (33). Molecular study shows that Tgfbr2 directly 
phosphorylates the PTH1R cytoplasmic domain. PTH 
couples  the  processes  of  bone  resorption  and  for-
mation by enforcing simultaneous internalization of 
Tgfbr2 and PTH1R (34) (Figure 1), which attenuates 
both TGF and PTH signaling in vivo. It is recognized 
that  transcriptional  factor  cAMP  response  element 
binding  protein  (CREB)  mediates  PTH  signaling  in 
osteoblasts, and PTH-CREB signaling pathway acts as 
an effective activator of BMP-2 expression (35).  
TGF-β and FGF signaling in bone 
TGF-βs and FGF-2, -4, and -6 have been proven 
to  be  inducers  of  osteoblast  proliferation  (a  higher 
extent for TGF-β and FGF-2) and inhibitors of alkaline 
phosphatase (ALP) activity and osteoblast minerali-
zation (36), indicating potential application for in vitro 
bone growth induction in bone tissue engineering. In 
addition, FGF acts downstream of TGF-β signaling in 
regulating  CNC  cell  proliferation  and  exogenous 
FGF-2  rescues  the  cell  proliferation  defect  in  the 
frontal primordium of Tgfbr2 mutants, demonstrating 
the biological significance of the TGF-β-mediated FGF 
signaling  cascade  in  regulating  frontal  bone  devel-
opment  (37).  Reports  also  show  that  FGF/FGFR3 
signals mediate some of the effects of TGF-β on em-
bryonic bone formation (38) (Table 3). 
TGF and Wnt signaling in osteoblast 
TGF-β cooperates with Wnt signaling, and pro-
motes  osteoblast  differentiation  of  human  mesen-
chymal stem cells (hMSCs). Knockdown of β-catenin 
with siRNA stimulated ALP activity and antagonized 
the inhibitory effects of TGF-β1 on bone sialoprotein 
expression. TGF-β1 activates β-catenin signaling via 
ALK5, Smad3, PKA, and PI3K pathways, and modu-
lates  osteoblastogenesis  via  ALK5,  PKA,  and  JNK 
pathways in hMSCs (39). Recent studies in differenti-
ating osteoblasts indicate that Wnt pathway induction 
stabilizes  β-catenin  and  increases 
TCF/LEF-dependent gene expression in parallel with 
β-catenin-independent  complex  formation  between Int. J. Biol. Sci. 2012, 8 
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TCF-4  and  Runx2.  Activation  of  either  Runx2  or 
TCF-4  coenhances  TCF  and  Runx2  activity  and  in-
creases  TGFβRI  expression.  Overall,  Wnt  pathway 
induction  has  complex  stimulatory  and  inhibitory 
effects on TGF-β activity (40) (Table 3).  
TGF-β and Ihh signaling in bone 
Expression  of  Indian  hedgehog/parathyroid 
hormone-related  protein  (Ihh/PTHrP)  signaling  in 
the growth plate is decreased in Smad4 mutant mice. 
The  cultured  mutant  metatarsal  bones  failed  to  re-
spond  to  TGF-β1.  These  findings  indicate  that 
Smad4-mediated  TGF-β  signals  are  required  for 
maintaining the normal organization of chondrocytes 
in the growth plate (41), which is important for nor-
mal endochondral ossification. 
Interplay between TGF-β and BMP signaling in osteoblast 
and bone 
TGF-β1  strongly  enhances  ectopic  bone  for-
mation  induced  by  BMP-2,  with  the  resulting  bone 
volume being five-fold greater than that induced by 
BMP-2  alone  (42).  Evidence  shows  that  increased 
BMPR-IB  by  TGF-β1,  FGF-2,  and  PDGF-AB  signifi-
cantly enhances BMP-2-induced osteogenic functions 
in  vitro  (43).  Results  demonstrate  that  BMPRII  and 
ActRII are the functional type II TGF-β receptors in 
BMP-9-induced  osteogenic  differentiation  of 
C3H10T1/2 cells (44), indicating a strong connection 
between  TGF-β1  and  BMP  signaling  in  osteoblast 
differentiation (Table 3).  
BMP SIGNALING IN OSTEOBLAST 
DIFFERENTIATION AND BONE 
FORMATION 
BMPs  have  widely  recognized  roles  in  bone 
formation  during  mammalian  development  and  ex-
hibit  versatile  functions  in  the  body,  indicating  po-
tential for therapeutic use. Studies have elicited BMPs 
in mice to promote the rehabilitation of critical-size 
bone defects, which renders them useful in the field of 
tissue  engineering  and  regeneration.  Recent  discov-
eries  will  shed  light  on  better  understanding  of  in-
trinsic  BMP  signaling  and  the  crosstalk  with  Wnt, 
Notch, FGF and Hh signaling on osteoblast differen-
tiation and bone formation.  
Canonical BMP signaling in bone (BMPs, re-
ceptors, Smads) 
BMP-2, 4, 5, 6, and 7 all have strong osteogenic 
capacity.  Addition  of  BMP-2  vastly  increases  oste-
ocalcin (45) and a short-term expression of the BMP-2 
is necessary and sufficient to irreversibly induce bone 
formation (46). BMP-7 induced the expression of os-
teoblastic differentiation markers such as ALP activity 
and accelerated calcium mineralization (47-48). In vivo 
genetic studies using a Prx1-cre model demonstrated 
that  the  absence  of  locally  produced  BMP-7  has  no 
effect on postnatal limb growth and maintenance of 
bone  mass,  indicating  other  BMPs  present  in  adult 
bone are sufficient to compensate for the absence of 
BMP-7 (49). Loss of both BMP-2 and BMP-4 resulted 
in severe impairment of osteogenesis (50). However, 
limb  skeletogenesis  occurred  normally  despite  the 
absence of BMP-4, suggesting that BMP-4 is not re-
quired for bone formation and function in the limb 
(51).  Mice  lacking  the  ability  to  produce  BMP-2  in 
their limb bones have spontaneous fractures that do 
not resolve with time, other osteogenic stimuli cannot 
compensate for the absence of BMP-2 (52). BMP-2, not 
BMP-4, plays a crucial role for chondrocyte prolifera-
tion  and  maturation  during  endochondral  bone  de-
velopment (53) (Table 1).  
Trabecular bone volume of BMP-3-deficient mice 
is two-fold greater than that of wild-type mice (54). 
BMP-3 limits skeletal progenitor cell differentiation to 
mature osteoblasts, herein regulating adult bone mass 
(55). Overexpression of BMP-3 in chick wing bud re-
duces  BMP  signaling  results  in  expanded  skeletal 
elements (56). BMP-3 transgenic mice are subject to 
spontaneous rib fractures and have altered signaling 
through activin receptor type IIB (ActRIIB) in chon-
drocytes and the periosteum (57).  
BMP  receptors,  such  as  BMPR-II,  differentially 
modulate the responsiveness of target genes to BMP-2 
(58).  BMPR-II  and  ActR-IIB  are  able  to  compensate 
each other functionally in mediating BMP-2 signaling 
and BMP-2-induced osteoblast differentiation in 2T3 
cells  (59).  Normal  skeletons  develop  in  mice  with 
BMPR-II  deletion  via  Prx1-Cre,  indicating  that 
BMPR-II is not required for limb development or that 
the loss of BMPR-II is compensated by BMP utiliza-
tion of other type II BMP receptors (60). Conversely, 
mice  with  deletion  of  BMPR-IA  through  Col1-Cre 
have  increased  bone  volume  (61),  shortened  limbs, 
almost complete agenesis of the autopod (62), small 
body size, irregular calcification and low bone mass 
(63) (Table 1). Decreased osteoclastogenesis through 
the RANKL-OPG pathway was reported to contribute 
to the increased bone mass in trabecular bone (64). 
Neogenin, a transmembranous protein, was re-
ported to regulate BMP receptor association with lipid 
raft,  where  BMP  induces  canonical  Smad1/5/8 
phosphorylation  (65-66).  Overexpressing  BMP  sig-
naling through ALK2 will lead to ectopic phosphory-
lation of Smad1/5/8 (67). Osteoblast-specific Smad1 
conditional knockout mice developed an osteopenic 
phenotype  and  partial  inhibition  of  BMP  signaling Int. J. Biol. Sci. 2012, 8 
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(68). Combined loss of Smads 1/5/8 results in severe 
chondrodysplasia (69) (Table 1). If Smad1 is modified, 
it can modulate BMP-mediated osteogenesis (70) and 
the  intensity  of  BMP  signals  can  be  determined  by 
BMP  receptors  via  Smad1  C-terminal  phosphoryla-
tion  (71).  These  finding  demonstrated  that 
Smad1/5/8  are  intracellular  signaling  proteins  that 
transduce  signals  elicited  by  members  of  BMP  sig-
naling in osteoblasts. 
Smad4 is the only common Smad for both TGF-β 
and BMP signaling. Targeted disruption of Smad4 in 
mice results in numerous developmental defects and 
cancer formation in various tissues. Smad4-deficient 
mice died at E7.5-E9.5 without head-fold and anterior 
embryonic  structures,  and  with  impaired  respon-
siveness  to  TGF-β-induced  gene  expression  (72). 
Smad4-mediated TGF-β signaling is also reported to 
be  important  in  the  inhibition  of  oncogenesis  (73). 
Myocardial deletion of Smad4 in mice  causes misa-
lignment of the cardiac outflow tract (74), highlighting 
essential roles of this co-Smad in mediating signaling 
of  the  TGF-β  superfamily.  Conditional  deletion  of 
Smad4 in osteoblast leads to lower bone mineral den-
sity,  decreased  bone  volume,  decreased  bone  for-
mation rate, and a reduced number of osteoblasts (26). 
Control  of  Smad4  is  a  good  way  to  regulate  bone 
formation.  FAM  and  Ectodermin/Tif1gamma  (Ecto) 
were  reported  to  respectively  regulate  the 
de-ubiquitination  and  ubiquitination  of  Smad4 
(75-76).  On  the  other  hand,  Smad6  competes  with 
R-Smad  and  forms  a  non-functional  complex  with 
Smad4,  which  will  inhibit  BMP  signaling  in  bone 
formation. Smad6 is involved in a negative feedback 
loop regulating BMP signaling (77) and is required to 
limit BMP signaling during endochondral bone for-
mation (78). Smad6/Smurf1 double transgenic  mice 
show  severely  delayed  endochondral  ossification 
compared to the Smad6 knockout (79). Smurf1, with 
its WW domain, specifically binds to the PY motif of 
Smad6  and  transports  Smad6  into  the  cytoplasm. 
When Smad6 is in its rest state, it is mainly localized 
in the nucleus (80). 
Non-canonical BMP signaling function in bone 
The  importance  of  canonical  BMP  signaling  is 
well established, but the necessity for non-canonical 
(Smad-independent) signaling during these processes 
is also important. TAK1 is a factor that is involved in 
the fine-tuning of BMP effects during osteogenic de-
velopment  (81).  Osteoblast-specific  deletion  of  Tak1 
resulted in clavicular hypoplasia and delayed fonta-
nelle fusion, a phenotype similar to the cleidocranial 
dysplasia  observed  in  human  haploinsufficient  for 
Runx2  (82)  (Table  1).  Mechanistic  analysis  revealed 
that the TAK1-MKK3/6-p38 MAPK axis phosphory-
lated Runx2, promoting its association with the coac-
tivator  CREB-binding  protein  (CBP),  which  is  re-
quired to regulate osteoblast genetic programs  (82). 
Surprisingly,  deletion  of  TAK1  seems  to  affect  not 
only activation of the p38 MAPK signaling cascade, 
but also activation of the BMP-responsive Smad1/5/8 
(83). Smad and MAPK pathways act synergistically in 
the BMP pathway controlling limb development (84). 
The  coordinated  activity  of  Runx2  and 
BMP/TGF-β-activated  Smads  is  critical  for  the  for-
mation  of  the  skeleton.  TGF-β/BMP2  signaling, 
MAPK dependent phosphorylation, and Runx2 sub-
nuclear targeting converge to induce the osteogenic 
phenotype (85).  
Crosstalk between BMP and Notch, Hh, FGF, 
as well as Wnt signaling in osteoblasts and 
bone 
Runx2, Dlx5, and Osx in osteoblasts and bone 
Runx2 is a master transcription factor, and both 
endochondral and intramembranous bone formation 
are totally absent in Runx2-null mice (86). Autocrine 
BMP production is necessary for the Runx2 transcrip-
tion  factor  to  be  active.  Additionally,  BMPs  and 
Runx2  cooperatively  interact  to  stimulate  osteoblast 
gene expression (87), and direct evidence shows that 
Runx2 is essential for the execution and completion of 
BMP2  signaling  for  osteoblast  differentiation  (88). 
BMP-activated Smads interact with Runx2 to induce 
osteoblast-specific gene expression in C2C12 cells (86). 
Smad1 interacts with Runx2 on the promoter of target 
genes  and  controls  osteoblast  gene  expression  and 
differentiation (89). Mutations in Runx2 may lead to 
an  autosomal-dominant  human  bone  disease  called 
cleidocranial dysplasia, which is related to impaired 
Smad signaling and the target the of Runx2 activity 
during bone formation (90).  
However,  BMP-Smads  can  also  function  inde-
pendently  of  Runx2.  Osterix  (Osx),  which  is  indis-
pensable for preosteoblasts to differentiate into ma-
ture osteoblasts and form bone (91), was previously 
reported to be a Runx2-targeted gene. Osx induction 
by BMP-2 is completely abrogated by  the antisense 
blocking of Dlx5, indicating BMP-2-induced Osx ex-
pression  is  mainly  mediated  by  Dlx5,  but  not  by 
Runx2,  suggesting  that  Dlx5  may  directly  interact 
with  Osx  (92).  On  the  other  hand,  Dlx5  can  drive 
Runx2  expression  and  osteogenic  differentiation  in 
developing cranial suture mesenchyme (93), indicat-
ing that Dlx5 can work as an upstream gene of Runx2. 
Recently,  Akt,  a  member  of  the  ser-
ine/threonine-specific  protein  kinase,  was  found  to Int. J. Biol. Sci. 2012, 8 
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phosphorylate Osx and Dlx5 (94). Akt activation in-
creases  protein  stability,  osteogenic  activity,  and 
transcriptional activity of Osx and Dlx5 (95), revealing 
that Osx regulates bone formation through different 
signaling  pathways,  including  a  novel  mechanism 
involving Akt during osteoblast differentiation. 
BMP and Wnt signaling in bone 
Wnt3A and BMP-9 enhanced each other's ability 
to induce ALP in MSCs (96). In vitro deletion of the 
β-catenin gene inhibits osteoblast proliferation, alters 
osteoblast  differentiation,  and  reduces  the  respon-
siveness  of  osteoblasts  to  BMP-2  treatment  (97).  In-
teractions between β-catenin and Runx2 play an im-
portant role in BMP-9-induced osteogenic differentia-
tion of MSCs (96). On the other hand, BMPR1A spe-
cifically  deleted  in  osteoblasts  leads  to  a  significant 
increase in bone mass, which is partially due to hy-
peractivated  Wnt  signaling  (98)  and  increased  ex-
pression of sclerostin (Wnt receptor antagonist) and 
Dkk1 activity. It has been shown that both sclerostin 
and DKK1 act physiologically as downstream mole-
cules of BMP signaling to inhibit canonical Wnt sig-
naling  and  therefore  negatively  regulate  bone  mass 
(99)  (Figure  2).  Loss-of-function  of  either  DKK1  or 
SOST, which are downstream targets of BMPs, causes 
a  high  bone  mass  phenotype  in  humans  and  mice, 
suggesting an important role of DKK1 and SOST for 
bone mass regulation (100) (Table 3). 
BMP and FGF signaling in bone 
FGF  signaling  was  reported  to  interplay  with 
BMP signaling on bone formation. FGF-2 and FGF-9 
increased  expression  of  other  osteogenic  factors 
BMP-2  and  TGF-β1,  and  endogenous  FGF/FGFR 
signaling  is  a  positive  upstream  regulator  of  the 
BMP-2 gene in calvarial osteoblasts (101). FGF-2 and 
BMP-2 have a synergistic effect on fracture healing: 
FGF-2  has  a  critical  function  at  early  stage  while 
BMP-2  promotes  mineralization  at  later  stage  (102). 
FGF-2 null mice have impaired nuclear accumulation 
of  Runx2  and  hindered  BMP-2  induced  bone  for-
mation and ALP activity (103). Runx2 is an important 
mediator of the expression of BMP-2 in response to 
FGF stimulation in cranial bone development  (104). 
FGF and BMP synergy on osteogenesis may be mod-
ulated through Rnnx2 activation (Table 3). 
BMP and Notch signaling in osteoblasts 
Similar  synergy  is  found  in  Notch  and  BMP 
crosstalk:  activating  Notch  signaling  enhanced 
BMP-induced ALP activity and formation of calcified 
nodules in vitro (105). Notch inhibition results in de-
creased ALP activity and decreased promoter activity 
of BMP target genes (106). Notch signal transduction 
pathway genes, Lfng, Hey1, and Hes1, are differen-
tially  regulated  by  BMP-2  and  TGF-β.  These  genes 
might  function  as  the  focal  point  for  interaction  of 
Smad and Notch signaling during osteoblast differ-
entiation (107). Functional Notch signaling is required 
for BMP4-induced inhibition of myogenic differentia-
tion (108), which may be beneficial to osteoblast dif-
ferentiation.  
BMP, Hh, and FGF signaling in osteoblasts and bone 
Sonic hedgehog (Shh) is involved in osteoblast 
differentiation by cooperating with BMP-2 (109). Shh 
stimulates  BMP-2  promoter  activity  and  osteoblast 
differentiation.  The  effects  of  Shh  are  mediated  by 
Gli2, a powerful activator of BMP-2 gene expression, 
which is required in turn for normal osteoblast dif-
ferentiation  (110).  In  the  developing  axial  skeleton, 
sequential  Shh  and  BMP  signals  are  required  for 
specification of a chondrogenic fate in presomitic tis-
sue (111). On the other hand, BMP activity negatively 
regulates  Shh  transcription  and  a  BMP-Shh  nega-
tive-feedback loop serves to confine Shh expression 
during limb development (112) (Table 3).  
Ihh is found to be required for BMP-induced os-
teogenesis of a limb-bud cell line in culture. Ihh sig-
naling is directly required for the osteoblast lineage in 
developing long bones. Ihh functions in conjunction 
with other factors such as BMPs to induce osteoblast 
differentiation. In vivo, Ihh acts on potential progeni-
tor  cells  to  promote  osteoblast  differentiation  and 
prevent  chondrocyte  differentiation  (113).  Ihh  and 
BMP  synergistically  induce  ALP  activity.  Evidence 
indicates a stimulatory role for osteoblast-expressed 
Ihh  in  bone  formation  in  a  positive  feedback  loop 
(114). Conditional knockout Smad1/5 mice developed 
chondrodysplasia and exhibited abnormal growth at 
the end of bones. The molecular mechanism under-
lying  the  defects  in  conditional  knockout  Smad1/5 
mice appears to be an imbalance in the cross-talk be-
tween the BMP, FGF, and Ihh/PTHrP pathways (69), 
indicating  that  BMP,  FGF,  and  Ihh/PTHrP  is  im-
portant for normal long bone development (Table 3). 
NEGATIVE REGULATION OF 
TGF-β/BMP SIGNALING IN 
OSTEOBLAST DIFFERENTIATION AND 
BONE FORMATION  
TGF-β  and  BMP  signaling  is  under  elaborate 
regulation  to  maintain  correct  patterning  and  mor-
phogenesis of various tissues and organs. TGF/BMP 
signaling  in bone is negatively regulated through a 
number of mechanisms, including extramembranous Int. J. Biol. Sci. 2012, 8 
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regulation (ligand antagonist), intracellular regulation 
(Smurf  and  inhibitory  Smads),  and  transcriptional 
regulation (transcriptional repressors and epigenetic 
control).  
Ligand antagonists 
Antagonists targeting TGF-βs, such as Chordin 
(115) and Follistatin (116), and BMPs, such as Noggin 
(117), have been reported. Noggin, a BMP antagonist, 
negatively regulates BMP activities during vertebrate 
dorsal-ventral  patterning,  skeletogenesis,  and  joint 
formation (117). Noggin binds the domain that is re-
quired for BMP-7 to interact with BMP type I and type 
II  receptors  (118).  Transgenic  mice  with  overex-
pressed  Noggin  in  the  bone  microenvironment  are 
subject  to  osteopenia  and  fractures  and  exhbiti  de-
creased trabecular bone volume and impaired osteo-
blastic function (119-120). Noggin suppression may be 
a novel strategy for the treatment of osteolytic bone 
metastases (121).  
Ubiquitin ligase mediated degradation  
Smurf1  and  Smurf2  are  E3  ubiquitin  ligases 
known to suppress TGF-β signaling through degra-
dation of Smads and receptors for TGF-β and BMPs 
(122).  Smurf1  interacts  with  BMP-activated  Smad1 
and 5 and to mediate degradation of these Smad pro-
teins  as  well  as  Runx2  (123).  Smurf1-deficient  mice 
exhibit an age-dependent increase of bone mass (124). 
Smurf2  has  been  reported  to  form  a  complex  with 
Smad2 and then target SnoN for degradation  (125). 
Smurf2-transgenic mice exhibited decreased articular 
cartilage area and subchondral sclerosis (126). In ad-
dition, some proteins (e.g. CHIP, carboxyl terminus of 
Hsc70-interacting protein) inhibit the signaling activi-
ties  of  Smad1/5  by  recruiting  Smad1/5  from  the 
functional  R-/Co-Smad  complex  and  further  pro-
moting  the  ubiquitination  and  degradation  of 
Smad1/5 in a chaperone-independent manner (127). 
Other  proteins,  such  as  the  serine/threonine  kinase 
Fused (Fu), can function in concert with the E3 ligase 
Smurf  to  regulate  ubiquitination  and  proteolysis  of 
the BMP receptor (128). 
Transcriptional repressors  
In the nucleus, transcriptional repressing factors 
Ski  and  SnoN  play  a  negative  role  together  with 
I-Smads  (129)  to  disrupt  the  formation  of  the 
TGF-β-induced  functional  Smad-DNA  complex  and 
thereby inhibit target gene expression (130). Since the 
Ski-binding surface on Smad4 significantly overlaps 
with the surface required for binding R-Smad phos-
phorylated  tails,  binding  to  Ski  or  SnoN  interferes 
with the interaction between Smad4 and phosphory-
lated  R-Smads  and  disrupts  the  active  heteromeric 
Smad4/R-Smad  complex  (131).  Ski  and  SnoN  also 
prevent  Smads  from  binding  to  the  transcriptional 
coactivator  p300/CBP  (131)  which  is  important  in 
skeletogenesis. 
Epigenetic regulation  
Epigenetics is an essential mechanism to control 
gene expression and fundamental cellular processes. 
DNA  methylation  is  important  in  the  regulation  of 
ALPL  expression  through  the  osteoblast-osteocyte 
transition  (132).  Smad2-mediated  transcription  re-
quires  the  histone  acetyltransferase  p300,  which  is 
required for the ability of Smad2 to mediate activin 
and  TGF-β  signaling  (133).  Mutation  of  lysine  at 
Lys-19, Lys-20, and Lys-39 abolished Smad2 acetyla-
tion  in vivo  and  prevented  nuclear  accumulation  of 
Smad2 and subsequent TGF-β and activin responses 
(134). Smad7 interacts with specific histone deacety-
lases (HDACs), which are able to deacetylate Smad7 
(135).  This  is  significant  since  acetylation  of  Smad7 
protects  it  against  ubiquitination  and  degradation 
mediated by the ubiquitin ligase Smurf1 (136).  
Runx2 is a global regulator of osteogenesis and is 
crucial for regulating the expression of bone-specific 
genes. Runx2 is controlled by a dynamic equilibrium 
of  acetylation,  deacetylation,  and  ubiquitination. 
BMP-2  signaling  stimulates  p300-mediated  Runx2 
acetylation,  which  increases  transactivation  activity 
and inhibits Smurf1-mediated degradation of Runx2. 
HDAC4 and HDAC5 deacetylate Runx2 and lead to a 
Smurf-mediated  degradation  (137).  BMP-induced 
non-Smad ERK signaling pathway cooperatively reg-
ulates osteoblast differentiation, in part, through in-
creasing  the  stability  and  transcriptional  activity  of 
Runx2 or increasing Runx2 acetylation by p300 (138). 
On the other hand, studies suggest that NFATc1 acts 
as  a  transcriptional  co-repressor  of  osteocalcin  pro-
moter possibly in an HDAC-dependent manner (139). 
These findings demonstrate the importance of epige-
netic regulation on bone formation and its important 
medical implications since TGF-β/BMPs and Runx2 
are of great interest with regard to the development of 
therapeutic agents against bone diseases. 
TGF-β/BMP SIGNALING IN DISEASES 
AND CLINICAL APPLICATIONS 
TGF-β/BMP signaling in human diseases  
Basic  research  has  contributed  greatly  to  our 
understanding of human skeletal diseases caused by 
mutations related to TGF-β/BMP signaling (Table 2). 
Fibrodysplasia ossificans progressiva (FOP) is a rare 
disabling disease caused by mutations in ALK2 (140) Int. J. Biol. Sci. 2012, 8 
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and  characterized  by  heterotopic  ossification  (141). 
Mutations in BMPR1B were recently demonstrated in 
two  affected  families  with  brachydactyly  type  A2 
(BDA2)  (142).  BDA2  is  characterized  by  hypo-
plasia/aplasia  of  the  second  middle  phalanx  of  the 
index  finger  and  sometimes  the  little  finger.  BDA2 
was  first  described  by  Mohr  and  Wriedt  in  a  large 
Danish/Norwegian kindred and GDF5 (growth and 
differentiation  factor  5)  was  identified  as  a  novel 
BDA2 causing gene (142-143). Furthermore, two mu-
tations  (N445K,  T)  of  GDF5  in  patients  developed 
synostosis syndrome (144). An additional functional 
mechanism for the pathogenesis of BDA2 is duplica-
tion of a regulatory element that affects the expression 
of BMP2 in the developing limb (145). Mutations in 
BMP antagonist NOGGIN cause brachydactyly type B 
(BDB), which is characterized by terminal deficiency 
of fingers and toes (146). Mutations of Sost (antagonist 
of BMPs) are associated with sclerosteosis which is a 
disorder featuring increased bone density (147). Mu-
tations  of  the  TGF-β1  gene  on  chromosome 
19q13.1-q13.3 was reported to be the cause for camu-
rati-engelmann disease (CED) characterized by bone 
pain and osteosclerosis affecting the diaphysis of long 
bones  (148).  Recently,  a  new  TGF-β1  mutation 
(E169K) in exon 2 was identified in a Chinese family 
(149) which developed CED (Table 2).  
Except for the skeletal disorder, disruptions  of 
TGF-β/BMP  signaling  also  cause  other  human  dis-
eases. BMP-15 defects are involved in the pathogene-
sis of hypergonadotropic ovarian failure in humans, 
which  leads  to  female  infertility  (150).  Mutation  of 
BMPRII  is  linked  to  the  development  of  primary 
pulmonary  hypertension  (PPH)  and  features  the 
widespread  occlusion  of  small  pulmonary  arteries, 
which leads to sustained elevation of pulmonary ar-
terial pressure (151) (Table 2). Germline mutations of 
the gene encoding BMPR-IA results in juvenile poly-
posis,  an  autosomal  dominant  gastrointestinal 
hamartomatous  polyposis  syndrome  in  which  pa-
tients are at risk for developing gastrointestinal can-
cers (152). Moreover, BMPs have been implicated in 
periodontal disease (153), osteoarthritis (154), and the 
tumor metastasis. Indeed, BMP-2 may facilitate bone 
metastasis in gastric cancer (155). These findings in-
dicate  the  importance  of  TGF-β/BMPs  signaling  in 
bone development and homeostasis. 
It is hoped that basic research on disease and its 
underlying  mechanism  may  open  new  avenues  for 
the generation of antagonists, small inhibitory mole-
cules, or novel delivery systems that target bone dis-
eases. A small molecule inhibitor of BMP type I re-
ceptor activity has been demonstrated to be useful in 
treating FOP and heterotopic ossification syndromes 
(156). TGF-β type I receptor kinase inhibitor down-
regulates rheumatoid synoviocytes and prevents the 
arthritis  (157).  TGF-β1–induced  migration  of  bone 
mesenchymal stem cells couples bone resorption with 
formation, so modulation of TGF-β1 activity could be 
an effective treatment for bone remodeling diseases 
(158). The delivery of TGF-β3 with an injectable cal-
cium-phosphate matrix at the supraspinatus tendon 
footprint  has  promise  to  improve  healing  after  soft 
tissue repair (159).  
 
 
Table 2. TGF-β/BMP mutations involved in human diseases 
Gene  Disease  Defects  Refer 
ALK2  fibrodysplasia ossification progres-
sive (FOP) 
ectopic bone formation   (173) 
(140) 
NOGGIN(NOG)  Brachydactyly type B (BDB)  terminal deficiency of fingers and toes  (146) 
SOST  sclerosteosis   increased bone density   (147) 
BMP15  hypergonadotropic ovarian failure  a common cause of female infertility  (150) 
BMPR-II  primary pulmonary hypertension 
(PPH) 
obstruction of pre-capillary pulmonary arteries  (151) 
GDF5  brachydactyly type A2 (BDA2) 
 
hypoplasia/aplasia of the second middle 
phalanx of the index finger and sometimes the 
little finger.  
 
(142) 
BMPR1B  (142-143) 
conserved regulatory element down-
stream of BMP2 
(145) 
BMPRIA  juvenile polyposis  early developing gastrointestinal cancers  (152) 
TGF-β 1  camurati-engelmann disease (CED)  characterized by bone pain and osteosclerosis 
affecting the diaphysis of long bones 
(148-149) 
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Table 3. Crosstalk between TGF-β/BMP signaling and other signaling molecules in osteoblast and bone 
Gene  Crosstalk signaling  Results  Refer 
Tgfbr2  PTH type I receptor  increased bone mass  (33) 
PTH-CREB  BMP-2 expression  osteoblastogenesis  (35) 
FGF2  Tgfbr2 mutantnormal  regulates frontal bone  (37) 
FGF-- FGFR3  TGF-beta  mediates embryonic bone formation  (37) 
TGF-β 1  beta-catenin  osteoblastogenesis  (39) 
Wnt and TGF-β  TCF,Runx2 TβRI   Runx2 osteoblast maturation  (40) 
Smad4 mutant  Ihh/PTHrP  ×TGF-β 1 response  (41) 
TGF-β1  BMP-2    ectopic bone formation  (42) 
Wnt3A   BMP-9   ALP  (96) 
β-catenin   responsiveness to BMP-2  alters osteoblast differentiation  (97) 
β-catenin and Runx2   BMP-9-induced   osteogenic differentiation  (96) 
BMPR1A   Wnt (SOST, Dkk1)  bone mass  (99) 
FGF-2,-9 FGF/FgfR   BMP-2 and TGFbeta-1  osteogenic expression  (101) 
Notch  BMP-induced ALP   Smad and Notch  (105) 
Shh (Gli2)   BMP-2 promoter activity  normal osteoblast differentiation  (110) 
Ihh  BMP-induced osteogenesis  bone formation  (113) 
Ihh and BMP  ALP, Ihh expression  long bone development  (114) 
Note: decrease; increase;  stimulate; × block 
 
 
TGF-β /BMP signaling in clinical applications 
Currently,  two  BMP  products  have  been  ap-
proved by the Food and Drug Administration (FDA) 
for clinical applications to treat fractures of long bones 
and improve intervertebral disk regeneration through 
a purified collagen matrix respectively infused with 
BMP-2 (Medtronic) or OP-1 BMP-7 (Stryker Biotech) 
and implanted at the site of the fracture. BMP treat-
ment for acute open tibial fractures may be more fa-
vorable  economically  (160).  Combination  of  BMP-7 
with a type-one collagen carrier has been the subject 
of  increasing  interest.  BMP-7  in  combination  with 
osteosynthesis  revision  and  bone  grafting,  or  with 
bone grafting alone, shows that there is no periopera-
tive or postoperative complications in patients (161). 
The application of BMP-7 in a total of 19 joint fusions 
(ankle,  subtalar,  talonavicular,  pubic  and  sacroiliac) 
resulted in healing rates of 90% and satisfactory sub-
jective functional outcome in 70% of cases (162).  
With the use of BMPs increasingly accepted in 
spinal fusion surgeries, other therapeutic approaches 
targeting BMP signaling are emerging beyond appli-
cations to skeletal disorders. BMP-7 is also regarded 
as  a  strong  candidate  for  the  clinical  treatment  of 
chronic kidney disease (CKD)  (163). Administration 
of  BMP-7  prevents  the  development  of  adynamic 
bone disease in a preclinical model of chronic kidney 
failure (164). TGF-β/BMPs have also been used as the 
prognostic  biomarkers.  For  instance,  GDF-15  has 
emerged as a prognostic biomarker in acute coronary 
syndrome trial populations (165) and in cardiac and 
vascular dysfunction and disease (166). GDF-11 may 
be  a  novel  diagnostic  and  prognostic  biomarker  in 
patients  with  colorectal  cancer  (167).  Additionally, 
GDF-5 has emerged as a therapeutic target for rheu-
matic  diseases  (168).  Recent  applications  graft  BMP 
peptides corresponding to residues 73-92, 89-117, and 
68-87 of BMP-2, BMP-7, and BMP-9 as adhesion pep-
tides  (GRGDSPC)  onto  polyethylene  terephthatalate 
(PET) surfaces to enhance osteogenic differentiation 
and  mineralization  of  pre-osteoblastic  cells  (169). 
These  engineered  biomaterials  for  enhanced  bone 
regneration  are  in  the  initial  trial  stage  of  develop-
ment.  
SUMMARY AND PERSPECTIVE 
Our understanding of bone is rapidly advancing 
with the use of new technology, such as conditional 
knockout  mice,  high-throughput  screening,  and  the 
discovery  of  newly  recognized  cross-talk  between 
TGF-β/BMP signaling and many other major signal-
ing pathways such as MAPK, Wnt, Hedgehog, Notch, 
and FGF. TGF-β/BMP signaling plays critical regula-
tory functions in osteoblast differentiation and bone 
formation. The signaling relays in each stage (ligands, 
receptors, Smads) are responsible for the final target 
gene  expression.  Perturbations  of  TGF-β/BMP  sig-Int. J. Biol. Sci. 2012, 8 
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naling  result  in  various  clinical  disorders  including 
cancers, bone diseases, and vascular diseases. Thus, 
there is great potential for the clinical applications of 
TGF-β/BMP  molecules  for  the  treatment  of 
bone-related  diseases,  such  as  FOP,  chronic  kidney 
disease,  brachydactyly  type  A2,  and  osteoporosis. 
More  importantly,  with  the  aging  population  ex-
pected to double over the next decade, the number of 
people  suffering  from  osteoporosis  is  likely  to  in-
crease dramatically and so is the cost of Medicare. The 
current cost of medical care associated with osteopo-
rosis (especially hip fractures) has been estimated at 
more  than  $17  billion  a  year.  As  such,  there  is  in-
creased pressure to elucidate the pathophysiology of 
bone diseases and the molecular mechanisms of skel-
etal remodeling in health and disease.  
 So far, BMP-2-and BMP-7-containing osteogenic 
implants have been used in over one million patients 
worldwide for the treatment of long bone nonunions, 
spinal fusions, and acute fractures. Apart from their 
recognized role in bone regeneration, BMPs have been 
used systemically to improve skeletal volume, kidney 
regeneration, glucose, and iron metabolism. There are 
still much to discover, including small molecule in-
hibitors with special target sites and better effective-
ness, as well as better delivery systems and reliable 
TGF-β/BMPs retention at target sites in vivo.  
ABBREVIATIONS  
PTH:  parathyroid  hormone;  ActR-II:  Activin 
type II receptor; ActR-IIB: Activin type II B receptor; 
TβR-II, Tgfbr2: TGF-β type II receptor; BMPR-II: BMP 
type  II  receptor;  AMHR-II:  AMH  type  II  receptor; 
ALK: Activin receptor-like kinase; BMPR-IA: Type I 
receptor  of  ALK-3;  BMPR-IB:  Type  I  receptor  of 
ALK-6; TAK1: TGF-β activation kinase1; TAB1: TAK1 
binding protein 1. 
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